Good evening :)
Place Order
Add to Watchlist

SeQuent Scientific Ltd

SEQUENT Share Price

184.411.43% (-2.68)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

SEQUENT Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

SEQUENT Performance & Key Metrics

SEQUENT Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
213.686.56
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.516.520.85%

SEQUENT Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

SEQUENT Company Profile

SeQuent Scientific Limited is a holding company that operates in pharmaceutical sector.

Investor Presentation

View older View older 

May 20, 2025

PDF
View Older Presentations

SEQUENT Similar Stocks (Peers)

Compare with peers Compare with peers 

SEQUENT Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.56
36.56
1Y Return
11.24%
11.24%
Buy Reco %
87.88
87.88
PE Ratio
22.97
22.97
1Y Return
0.35%
0.35%
Buy Reco %
74.19
74.19
PE Ratio
19.50
19.50
1Y Return
8.83%
8.83%
Buy Reco %
56.67
56.67
PE Ratio
56.09
56.09
1Y Return
11.44%
11.44%
Buy Reco %
72.00
72.00
PE Ratio
21.28
21.28
1Y Return
12.08%
12.08%
Buy Reco %
46.43
46.43
Compare with Peers

SEQUENT Sentiment Analysis

SEQUENT Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

SEQUENT Stock Summary · May 2025

In Q4 FY25, the company achieved a remarkable turnaround, reporting a profit after tax of INR 322 million, a 208.9% increase from the previous year’s loss, driven by an 11.2% revenue growth to INR 4,017 million. The formulations business thrived with nearly 20% growth, while the API segment showed signs of recovery, bolstered by strategic initiatives and a focus on operational efficiency. Despite challenges with cash flow conversion due to high inventory levels, management remains optimistic about future growth, particularly with the upcoming merger with Viyash Life Sciences, which is expected to enhance R&D capabilities and operational performance. The company is also expanding its companion animal health segment and pursuing opportunities in the CDMO space, positioning itself for sustained growth and improved margins.

SEQUENT Stock Growth Drivers
SEQUENT Stock Growth Drivers
7
  • Strong Financial Performance

    SeQuent Scientific Limited reported robust financial results for Q4 FY '25, achieving revenues of INR

  • Improved Margins and Profitability

    The company achieved a significant turnaround in profit after tax, moving from a loss in

SEQUENT Stock Challenges
SEQUENT Stock Challenges
5
  • Revenue Decline

    The company has experienced a 3% decline in revenue quarter-on-quarter, attributed to inventory buildup in

  • Limited Product Offering in Companion Animal Health

    Currently, the companion animal health segment constitutes less than 10% of the company's product offerings.

SEQUENT Forecast

SEQUENT Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

SEQUENT

SEQUENT

Income

Balance Sheet

Cash Flow

SEQUENT Income Statement

SEQUENT Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.89%, vs industry avg of 9.02%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.48% to 0.37%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue694.651,292.621,047.981,189.331,369.981,423.671,427.301,395.451,566.061,566.06
Raw Materialssubtract366.89486.44570.52600.59733.68842.41814.87789.201,394.551,394.55
Power & Fuel Costsubtract12.7714.6623.0624.7328.7533.8642.4535.46
Employee Costsubtract106.22113.83145.95165.06187.22231.37258.39250.57
Selling & Administrative Expensessubtract74.6894.7290.93108.27115.85132.65139.02138.35
Operating & Other expensessubtract82.5964.2883.92110.2792.8663.12219.02126.88
Depreciation/Amortizationsubtract40.0741.3441.9250.6250.6051.5455.6961.5466.4566.45
Interest & Other Itemssubtract28.3433.0732.8035.7124.3815.7735.5248.0960.7560.75
Taxes & Other Itemssubtract-3.0822.7210.2224.1741.1911.98-16.50-18.7722.4322.43
EPS-0.5315.981.912.823.841.65-4.87-1.440.880.88
DPS0.000.180.200.000.500.000.000.000.000.00
Payout ratio0.000.010.100.000.130.000.000.000.000.00

SEQUENT Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 20PDF
Feb 11PDF
Nov 13PDF
Sep 26PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 23PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF

Investor Presentation

Feb 3PDF
FY 2020FY 2020

Annual report

PDF

Investor Presentation

Jan 28PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

SEQUENT Stock Peers

SEQUENT Past Performance & Peer Comparison

SEQUENT Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
SeQuent Scientific Ltd213.686.56
Sun Pharmaceutical Industries Ltd36.565.950.96%
Cipla Ltd22.974.521.07%
Dr Reddy's Laboratories Ltd19.503.900.61%

SEQUENT Stock Price Comparison

Compare SEQUENT with any stock or ETF
Compare SEQUENT with any stock or ETF
SEQUENT
Loading...

SEQUENT Holdings

SEQUENT Shareholdings

SEQUENT Promoter Holdings Trend

SEQUENT Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SEQUENT Institutional Holdings Trend

SEQUENT Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SEQUENT Shareholding Pattern

SEQUENT Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding52.61%10.22%2.60%6.05%28.52%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

SEQUENT Shareholding History

SEQUENT Shareholding History

Dec '23MarJunSepDec '24Mar6.12%6.16%5.70%6.45%6.10%6.05%

Mutual Funds Invested in SEQUENT

Mutual Funds Invested in SEQUENT

No mutual funds holding trends are available

Top 5 Mutual Funds holding SeQuent Scientific Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
8.9064%1.53%0.07%15/112 (+2)
0.5847%6.80%1.04%11/27 (-1)
0.3448%1.57%-0.04%27/45 (-2)

Compare 3-month MF holding change on Screener

SEQUENT Insider Trades & Bulk Stock Deals

SEQUENT Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing SEQUENT stock

smallcases containing SEQUENT stock

Looks like this stock is not in any smallcase yet.

SEQUENT Events

SEQUENT Events

SEQUENT Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

SEQUENT Dividend Trend

No dividend trend available

SEQUENT Upcoming Dividends

SEQUENT Upcoming Dividends

No upcoming dividends are available

SEQUENT Past Dividends

SEQUENT Past Dividends

Cash Dividend

Ex DateEx DateSep 8, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 8, 2021

Cash Dividend

Ex DateEx DateAug 21, 2019

Final
Final | Div/Share: ₹0.20

Dividend/Share

0.20

Ex DateEx Date

Aug 21, 2019

Cash Dividend

Ex DateEx DateNov 20, 2017

Interim
Interim | Div/Share: ₹0.20

Dividend/Share

0.20

Ex DateEx Date

Nov 20, 2017

Cash Dividend

Ex DateEx DateSep 16, 2011

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 16, 2011

Cash Dividend

Ex DateEx DateSep 23, 2010

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Sep 23, 2010

SEQUENT Stock News & Opinions

SEQUENT Stock News & Opinions

Corporate
Sequent Scientific allots Equity shares

Sequent Scientific has approved the issue and allotment of 3,000 Equity Shares of Rs. 2/- each fully paid to one Employee at an exercise price of Rs. 86/- per equity share on exercise of the options granted to him under SeQuent ESOP 2020.Powered by Capital Market - Live

5 days agoCapital Market - Live
Earnings
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter

Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales401.70361.20 11 1551.371369.73 13 OPM %11.518.93 -10.434.48 - PBDT32.7723.83 38 115.7324.28 377 PBT16.657.35 127 49.28-37.26 LP NP9.32-0.92 LP 21.88-35.88 LP Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Sequent Scientific to hold board meeting

Sequent Scientific will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Sequent Scientific consolidated net profit declines 58.40% in the December 2024 quarter

Net profit of Sequent Scientific declined 58.40% to Rs 3.44 crore in the quarter ended December 2024 as against Rs 8.27 crore during the previous quarter ended December 2023. Sales rose 18.66% to Rs 390.81 crore in the quarter ended December 2024 as against Rs 329.36 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales390.81329.36 19 OPM %8.836.76 - PBDT25.3914.19 79 PBT8.41-1.27 LP NP3.448.27 -58 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Sequent Scientific announces board meeting date

Sequent Scientific will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Sequent Scientific receives CCI approval for composite scheme of amalgamation

Sequent Scientific announced that the Competition Commission of India vide its letter dated 21 January 2025 has approved the composite Scheme of amalgamation amongst Sequent Scientific, Symed Labs, Vandana Life Sciences, Appcure Labs, Vindhya Pharma (India), S.V. Labs, Vindhya Organics, Viyash Life Sciences, Geninn Life Sciences and Sequent Research and their respective shareholders and the creditors. Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Sequent Scientific allots 5.40 lakh equity shares under ESOP

Sequent Scientific has allotted 5,40,000 equity shares under ESOP on 23 November 2024. With this allotment, the paid up equity share capital has increased to Rs. Rs. 50,06,03,990/-consisting of 25,03,01,995 equity shares of Rs. 2/- each.Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Sequent Scientific consolidates its holdings in N-VET AB, Sweden and Alivira Italia SRL, Italy

Sequent Scientific has completed the acquisition of 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. The company also completed the acquisition of 3.75% stake from Renzo Rimondi and 1.25% from Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Sequent Scientific announces board meeting date

Sequent Scientific will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Sequent Scientific allots Equity Shares

Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020. Powered by Capital Market - Live

7 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of SeQuent Scientific Ltd (SEQUENT) today?

    The share price of SEQUENT as on 23rd June 2025 is ₹184.41. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on SeQuent Scientific Ltd (SEQUENT) share?

    The past returns of SeQuent Scientific Ltd (SEQUENT) share are
    • Past 1 week: -4.34%
    • Past 1 month: 4.87%
    • Past 3 months: 27.44%
    • Past 6 months: 5.16%
    • Past 1 year: 56.04%
    • Past 3 years: 91.10%
    • Past 5 years: 98.18%

  3. What are the peers or stocks similar to SeQuent Scientific Ltd (SEQUENT)?
  4. What is the market cap of SeQuent Scientific Ltd (SEQUENT) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SeQuent Scientific Ltd (SEQUENT) is ₹4608.27 Cr as of 23rd June 2025.

  5. What is the 52 week high and low of SeQuent Scientific Ltd (SEQUENT) share?

    The 52-week high of SeQuent Scientific Ltd (SEQUENT) is ₹240.70 and the 52-week low is ₹116.40.

  6. What is the PE and PB ratio of SeQuent Scientific Ltd (SEQUENT) stock?

    The P/E (price-to-earnings) ratio of SeQuent Scientific Ltd (SEQUENT) is 210.62. The P/B (price-to-book) ratio is 6.46.

  7. Which sector does SeQuent Scientific Ltd (SEQUENT) belong to?

    SeQuent Scientific Ltd (SEQUENT) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy SeQuent Scientific Ltd (SEQUENT) shares?

    You can directly buy SeQuent Scientific Ltd (SEQUENT) shares on Tickertape. Simply sign up, connect your demat account and place your order.